An unusual cause of spontaneous bleeding in the intensive care unit – mastocytosis: a case report by Koenig, Martial et al.
BioMed  Central
Page 1 of 3
(page number not for citation purposes)
Cases Journal
Open Access Case Report
An unusual cause of spontaneous bleeding in the intensive care unit 
– mastocytosis: a case report
Martial Koenig1, Jérôme Morel2, Jacqueline Reynaud3, Cécile Varvat2 and 
Pascal Cathébras*1
Address: 1Department of internal medicine, Centre Hospitalier Universitaire de Saint-Etienne, F-42055 Cedex 2, France, 2Department of intensive 
care, Centre Hospitalier Universitaire de Saint-Etienne, F-42055 Cedex 2, France and 3Department of haematology, Centre Hospitalier 
Universitaire de Saint-Etienne, F-42055 Cedex 2, France
Email: Martial Koenig - martial.koenig@chu-st-etienne.fr; Jérôme Morel - jerome.morel@chu-st-etienne.fr; 
Jacqueline Reynaud - jacqueline.reynaud@chu-st-etienne.fr; Cécile Varvat - celine.varvat@chu-st-etienne.fr; 
Pascal Cathébras* - pascal.cathebras@chu-st-etienne.fr
* Corresponding author    
Abstract
We report the case of a 39-year old male patient who presented with anaphylactoid shock and
diffuse bleeding with prolonged activated partial thromboplastin time at the emergency room. The
diagnosis of aggressive mastocytosis was suspected and then confirmed by raised tryptase level and
mastocytic infiltration of the bone marrow. The outcome was favorable with supportive measures,
antihistamine drugs, and imatinib mesylate.
Background
Mastocytosis is a rare and heterogeneous disease charac-
terized by the presence of excessive numbers of mast cells
in various organs, mainly the skin and the bone marrow
[1]. Systemic symptoms are related to mast cell degranu-
lation. Although heparin is one of the mediators released
by mast cells, spontaneous bleeding has been very rarely
reported in mastocytosis.
Case presentation
On December 2006 21th, a 39-year-old male patient of
North-African origin, non smoker and who did not drink
alcohol, with unremarkable family and personal medical
history, at the exception of a history of skin rash after
intake of aspirin, presented to the emergency room of a
general hospital with abdominal pain, vomiting, and a
diffuse skin rash. The patient was alert and afebrile. There
was no abdominal tenderness. Initially, blood pressure
was 170/90 mm Hg and pulse rate was 70/mn, but hemo-
dynamic parameters rapidly deteriorated despite fluid
infusion. Laboratory investigations revealed acute renal
failure (creatinine 211 μmol/L), hypokaliemia (2.6
mmol/l), hemoconcentration (protidemia 92 g/L), and
clotting tests showed prolonged activated partial throm-
boplastin time (aPTT) (187" versus 30" control value) and
prothrombin time (17"2 versus 11"8 control value). Blood
count showed hyperleucocytosis (18 × 109/L) mainly due
to a rise in neutrophil count (16 × 109/L) with a normal
platelet and eosinophil count. Haemoglobin level was
12.6 g/dL. C-reactive protein was only slightly elevated
(14 mg/L). The patient was transferred to the intensive
care unit of the university hospital because of anuria and
unexplained abnormalities of clotting tests. On admis-
sion, diffuse skin rash was still present. The patient pre-
sented signs of shock (blood pressure 80/60 mm Hg,
pulse rate 130/mn, anuria and agitation). Orotracheal
intubation was thus performed, and mechanical ventila-
tion and continuous hemofiltration were started. Epine-
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phrine infusion corrected hemodynamic status, and the
skin rash quickly disappeared. Septic or toxic shock were
the first hypotheses investigated, but no infection was
documented, and there was no argument for dissemi-
nated intravascular coagulation, since the platelet count
remained normal. Repeated clotting tests showed how-
ever an aPTT up to 200", a prothrombin time raised up to
90", and anti-Xa activity was 2.5 UI/mL. Fibrinogen was
1.8 g/L, antithrombin level was 56%. These abnormalities
persisted despite the infusion of 10 units of fresh frozen
plasma, and haemoglobin level dropped to 8.6 g/dl
because of diffuse bleeding at the sites of venous punc-
ture. Total body computed tomography showed no cere-
bral haemorrhage, no organomegaly, but an hematoma of
the duodenal wall was noticed. Gastroscopy revealed non-
specific oesophagitis without active bleeding. Medical
records revealed that the patient had not received any
anticoagulant treatment prior or since he was admitted to
the hospital, and thus the abnormalities of clotting tests
were attributed to an endogenous heparin-like factor pro-
duction. This hypothesis, combined with initial symp-
toms of vasoplegic shock, led the hemostasis specialist to
suggest to the clinicians the diagnosis of systemic masto-
cytosis, which was confirmed by subsequent workup,
including a serum tryptase level up to 200 μg/L (normal <
13) and a bone marrow biopsy showing multifocal infil-
trates of spindle-shaped mast cells [Figure 1]. The patient
was initially treated with fresh frozen plasma and red cell
transfusions, and then protamine was infused at a rate of
1200 UI/h combined with IV glucocorticoids, enteral H1
and H2 antihistamines, and imatinib mesylate (400 mg/
d). aPTT and prothrombin time were normalized within
four days. The patient's status allowed his discharge from
intensive care unit after 15 days. On clinical examination
in the internal medicine unit, urticaria pigmentosa with
Darier's sign (urtication reaction at the site of the papulo-
macular lesions when scratched) was demonstrated on
the trunk. The patient had not noticed these reddish-
brown spots before. Complementary workup revealed
long bones involvement on radiographics, diffuse bone
abnormality on technetium scintography, diminished
bone mineral density (lumbar T-score -1.4; femoral T-
score -0.8), and the presence of mastocytic infiltrates in
oesophageal wall. No skin biopsy was performed. C-kit
mutation D816V was not demonstrated. Serum tryptase
level was 13.5 μg/L (N < 13) on day 15. A final diagnosis
of aggressive systemic mastocytosis was established, and
the patient was discharged on day 30 with ranitidine, ceti-
rizine, glucocorticoids, alendronate, and imatinib
mesylate (200 mg/d). On his last follow-up visit in June
2008, he remained asymptomatic under the same treat-
ment at the exception of steroids which had been discon-
tinued.
Conclusion
Systemic mastocytosis is a rare disease characterized by
abnormal growth and accumulation of mast cells in vari-
ous organ [1]. It can follow a benign or indolent course,
or it may be associated with invalidating or even life-
threatening symptoms such as hypotension, syncope,
flushing, urticaria, bronchospasm, peptic ulcer disease,
diarrhea, malabsorption, osteoporosis, weigh loss and
fatigue [1]. Patients with aggressive systemic mastocytosis
usually present with enlarged liver, spleen, and lymph
nodes, with or without eosinophilia [1]. The diagnosis of
systemic mastocytosis is established by demonstrating
mast cell infiltration in an involved tissue, particularly the
bone marrow, using special staining techniques or flow
cytometry, but the measurement of serum tryptase is a
good screening test, since almost all patients with sys-
temic mastocytosis have serum tryptase levels exceeding
20 ng/mL [2]. Clinical pattern depends on mast cells bur-
den in different organs and release of clinically relevant
mediators such as histamine, leukotrienes, tryptase and
heparin [1,2]. Kinetics of blood clotting may be altered
due to fibrinogenolytic and anticoagulant activities of
tryptase and heparin respectively [3]. Severe bleeding
leading to the death of a patient with systemic mastocyto-
sis due to heparin-like anticoagulant has been recently
reported [4], and may represent a difficult diagnosis and a
therapeutic challenge in the emergency room. The treat-
ment of systemic mastocytosis is mainly focused on
avoidance of triggering factors (e.g. physical stimuli such
as heat or cold, alcohol, drugs such as aspirin and other
NSAIDS) and symptomatic therapy (H1 and H2 antihista-
mines, proton pump inhibitors, antileukotrienes, anti-
cholinergics, glucocorticoïds, and epinephrine in case of
systemic hypotension). In aggressive forms of systemic
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mastocytosis, treatments such as interferon alpha,
cladribin, and imatinib mesylate should to be considered.
Imatinib seems to be more effective in patients without
the D816V C-kit mutation [2].
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